Table Graph
      published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsACTIV-6, 2022 1.10 [0.64; 1.91] ACTIV-6 (ivermectine), 2023 0.94 [0.58; 1.53] COVID-OUT (fluvoxamine), 2022 1.17 [0.57; 2.40] COVID-OUT (ivermectin), 2022 1.39 [0.72; 2.69] 1.10[0.82; 1.47]ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 202240%2,659lownot evaluable death D28detailed resultsEPIC-HR, 2021 0.04 [0.00; 0.70] Fischer (all doses), 2021 0.22 [0.01; 6.60] MOVe-OUT, 2021 0.06 [0.00; 1.05] PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30] TOGETHER, 2021 0.69 [0.37; 1.30] 0.28[0.07; 1.04]EPIC-HR, 2021, Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 2021537%5,108moderatenot evaluable deathsdetailed resultsACTIV-6 (ivermectine), 2023 2.01 [0.07; 59.98] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61] COPE – Coalition V, 2022 1.56 [0.39; 6.24] COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28] EPIC-HR, 2021 0.04 [0.00; 0.70] Fischer (all doses), 2021 0.22 [0.01; 6.60] IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03] Lopez-Medina, 2021 0.50 [0.02; 14.95] MOVe-OUT, 2021 0.06 [0.00; 1.05] PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71] PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30] PRINCIPLE, 2021 1.65 [0.03; 83.12] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.26 [0.01; 5.88] TOGETHER, 2021 0.80 [0.43; 1.50] TOGETHER (ivermectine), 2022 0.87 [0.48; 1.58] 0.81[0.56; 1.17]ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COPE – Coalition V, 2022, COVID-PEP Severity (Skipper), 2020, EPIC-HR, 2021, Fischer (all doses), 2021, IVERCORCOVID19 (Vallejos), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022150%12,493lowlow deaths (time to event analysis only)detailed resultsTOGETHER, 2021 0.80 [0.43; 1.50] 0.80[0.43; 1.50]TOGETHER, 202110%1,472NAnot evaluable hospitalization or deathdetailed resultsACTIV 6 ivermectin, 2022 1.05 [0.43; 2.61] ALBERTA HOPE-Covid19, 2021 2.73 [0.14; 52.87] COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75] COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79] EPIC-HR, 2021 0.12 [0.06; 0.24] Hinks (ATOMIC2), 2021 0.91 [0.43; 1.92] IVERCORCOVID19 (Vallejos), 2020 0.66 [0.33; 1.30] MOVe-OUT, 2021 0.48 [0.30; 0.78] PINETREE (GS-US-540-9012), 2021 0.13 [0.03; 0.58] TOGETHER, 2021 0.76 [0.57; 1.02] 0.56[0.35; 0.89]ACTIV 6 ivermectin, 2022, ALBERTA HOPE-Covid19, 2021, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, EPIC-HR, 2021, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 20211071%8,891lowlow A EFFACER PCR-negative (end of follow-up)detailed resultsHinks (ATOMIC2), 2021 0.91 [0.57; 1.46] 0.91[0.57; 1.46]Hinks (ATOMIC2), 202110%295NAnot evaluable clinical deteriorationdetailed resultsCOVID-OUT (fluvoxamine), 2022 0.94 [0.65; 1.35] COVID-OUT (ivermectin), 2022 1.05 [0.76; 1.45] Lenze (STOP COVID 1), 2020 0.07 [0.00; 1.26] Lopez-Medina, 2021 0.56 [0.16; 1.95] PATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68] TOGETHER, 2021 0.64 [0.47; 0.87] TOGETHER (ivermectine), 2022 0.90 [0.70; 1.16] 0.84[0.68; 1.03]COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, PATCH Cohort 1 (Amaravadi), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022734%4,883moderatenot evaluable clinical improvementdetailed resultsACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18] COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] Lopez-Medina, 2021 1.07 [0.87; 1.32] PRINCIPLE, 2021 1.08 [0.95; 1.23] 1.08[1.00; 1.16]ACTIV 6 ivermectin, 2022, COVID-PEP Severity (Skipper), 2020, Lopez-Medina, 2021, PRINCIPLE, 202140%3,709lownot evaluable clinical improvement (14-day)detailed resultsACTION, 2021 1.01 [0.75; 1.37] COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.12[0.85; 1.47]ACTION, 2021, COVID-PEP Severity (Skipper), 2020213%658moderatenot evaluable clinical improvement (21-day)detailed resultsLopez-Medina, 2021 1.28 [0.79; 2.10] 1.28[0.79; 2.10]Lopez-Medina, 202110%400NAnot evaluable clinical improvement (28-day)detailed resultsACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18] 1.07[0.97; 1.18]ACTIV 6 ivermectin, 202210%1,591NAnot evaluable clinical improvement (time to event analysis only)detailed resultsACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18] Lopez-Medina, 2021 1.07 [0.87; 1.32] PRINCIPLE, 2021 1.08 [0.95; 1.23] 1.07[1.00; 1.16]ACTIV 6 ivermectin, 2022, Lopez-Medina, 2021, PRINCIPLE, 202130%3,314lownot evaluable hospitalizationdetailed resultsACTIV-6, 2022 0.45 [0.04; 5.03] ACTIV-6 (ivermectine), 2023 2.01 [0.37; 11.03] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76] Buonfrate (COVER-HIGH DOSE ARM C), 2022 6.33 [0.30; 132.38] COPE – Coalition V, 2022 0.77 [0.52; 1.13] COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75] COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79] Hinks (ATOMIC2), 2021 0.95 [0.46; 1.96] IVERCORCOVID19 (Vallejos), 2020 0.65 [0.32; 1.32] MOVe-OUT, 2021 0.49 [0.30; 0.79] PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93] PINETREE (GS-US-540-9012), 2021 0.28 [0.10; 0.77] PRINCIPLE, 2021 0.94 [0.50; 1.75] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.76 [0.30; 1.90] Rodrigues, 2021 2.02 [0.07; 62.02] Roozbeh, 2020 0.23 [0.02; 2.21] TOGETHER, 2021 0.76 [0.57; 1.02] TOGETHER (ivermectine), 2022 0.81 [0.59; 1.11] 0.75[0.64; 0.87]ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Buonfrate (COVER-HIGH DOSE ARM C), 2022, COPE – Coalition V, 2022, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, Roozbeh, 2020, TOGETHER, 2021, TOGETHER (ivermectine), 2022180%12,578moderatelow mechanical ventilationdetailed resultsCOPE – Coalition V, 2022 1.32 [0.46; 3.79] IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03] PRINCIPLE, 2021 0.50 [0.10; 2.60] 1.08[0.50; 2.31]COPE – Coalition V, 2022, IVERCORCOVID19 (Vallejos), 2020, PRINCIPLE, 202130%2,991moderatenot evaluable Recovery (time to event analysis only)detailed resultsACTIV-6 (ivermectine), 2023 1.02 [0.92; 1.13] Buonfrate (COVER-HIGH DOSE ARM C), 2022 0.79 [0.42; 1.48] 1.01[0.92; 1.12]ACTIV-6 (ivermectine), 2023, Buonfrate (COVER-HIGH DOSE ARM C), 202220%1,270lownot evaluable viral clearance detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Fischer (all doses), 2021 14.50 [1.70; 123.69] Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03] Rodrigues, 2021 1.00 [0.42; 2.39] TOGETHER, 2021 0.67 [0.42; 1.06] 0.90[0.76; 1.07]Chaccour, 2020, Fischer (all doses), 2021, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, TOGETHER, 2021639%1,386moderatenot evaluable viral clearance by day 14detailed resultsIVERCORCOVID19 (Vallejos), 2020 0.76 [0.45; 1.28] Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.55 [0.32; 0.94] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03] 0.79[0.59; 1.07]IVERCORCOVID19 (Vallejos), 2020, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021348%1,173moderatenot evaluable viral clearance by day 7detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Fischer (all doses), 2021 14.50 [1.70; 123.69] Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61] Rodrigues, 2021 1.00 [0.42; 2.39] TOGETHER, 2021 0.67 [0.42; 1.06] TOGETHER (ivermectine), 2022 0.99 [0.59; 1.67] 0.91[0.69; 1.20]Chaccour, 2020, Fischer (all doses), 2021, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Rodrigues, 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022640%1,313lownot evaluable emergency room observation for > 6 hours or hospitalizationdetailed resultsTOGETHER, 2021 0.64 [0.47; 0.87] 0.64[0.47; 0.87]TOGETHER, 202110%1,497NAnot evaluable ICU admissiondetailed resultsCOPE – Coalition V, 2022 0.84 [0.43; 1.63] PRINCIPLE, 2021 0.76 [0.18; 3.18] 0.82[0.45; 1.50]COPE – Coalition V, 2022, PRINCIPLE, 202120%2,489moderatenot evaluable recoverydetailed resultsACTIV-6, 2022 0.96 [0.86; 1.07] 0.96[0.86; 1.07]ACTIV-6, 202210%NAnot evaluable AE leading to drug discontinuationdetailed resultsFischer (all doses), 2021 0.88 [0.08; 9.94] MOVe-OUT, 2021 0.49 [0.23; 1.05] PINETREE (GS-US-540-9012), 2021 0.40 [0.08; 2.09] TOGETHER, 2021 1.38 [0.98; 1.95] 0.79[0.37; 1.69]Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 2021460%3,672moderatenot evaluable related AE (TRAE)detailed resultsEPIC-HR, 2021 1.76 [1.10; 2.82] 1.76[1.10; 2.82]EPIC-HR, 202110%1,349NAnot evaluable related SAE (TRSAE)detailed resultsEPIC-HR, 2021 1.01 [0.25; 4.05] 1.01[0.25; 4.05]EPIC-HR, 202110%1,349NAnot evaluable serious adverse eventsdetailed resultsFischer (all doses), 2021 1.34 [0.14; 13.10] Lenze (STOP COVID 1), 2020 0.17 [0.02; 1.49] Lopez-Medina, 2021 1.00 [0.14; 7.17] MOVe-OUT, 2021 0.70 [0.48; 1.03] PINETREE (GS-US-540-9012), 2021 0.25 [0.09; 0.69] 0.53[0.29; 0.98]Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021527%2,727lownot evaluable adverse eventsdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85] Chaccour, 2020 1.00 [0.20; 5.07] COVID-PEP Severity (Skipper), 2020 2.75 [1.80; 4.21] Fischer (all doses), 2021 1.05 [0.54; 2.02] Lenze (STOP COVID 1), 2020 0.98 [0.40; 2.38] MOVe-OUT, 2021 0.89 [0.71; 1.11] PINETREE (GS-US-540-9012), 2021 0.85 [0.61; 1.19] 2.31[0.92; 5.82]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Chaccour, 2020, COVID-PEP Severity (Skipper), 2020, Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021796%3,127moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-20 10:06 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons